Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03028181
Other study ID # 896-000-57-79
Secondary ID
Status Completed
Phase N/A
First received January 13, 2017
Last updated January 20, 2017
Start date January 2014
Est. completion date December 2016

Study information

Verified date January 2017
Source Wroclaw Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to assess and analyze some selected antioxidants and laboratory parameters during hospitalization of the patients with acute pancreatitis. It will allow to better understanding of the mechanisms of disease and the development of better diagnostic, treatment and monitoring.

It is an observational diagnostic study and does not involve any additional administration of medicinal substances, modification of treatment or dropping the use of routine methods of treatment of a disease. The study procedure includes detailed personal medical history as separate document like as a routine medical interview, and three times taking a small amount of venous blood (together about 15 ml), in the first, third, and seventh day of hospitalization (in the case of longer hospital treatment).


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- The patients were classified into the group of patients with acute pancreatitis (AP) due to clinical symptoms (acute onset of a persistent, severe, epigastric pain with tenderness on palpation on physical examination), personal interview and clinical method used in the diagnosis of pancreatitis - laboratory tests (elevation in serum lipase or amylase to three times or greater than the upper limit of normal) and characteristic findings of acute pancreatitis on imaging (contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI) or transabdominal ultrasonography). In patients with characteristic abdominal pain and elevation in serum lipase or amylase to three times or greater than the upper limit of normal, no imaging was required to establish the diagnosis of acute pancreatitis. In patients with abdominal pain that was not characteristic for acute pancreatitis or serum amylase or lipase levels that were less than three times the upper limit of normal, or in whom the diagnosis was uncertain, the investigators performed abdominal imaging with a contrast-enhanced abdominal CT scan to establish the diagnosis of acute pancreatitis and to exclude other causes of acute abdominal pain. In patients with severe contrast allergy or renal failure, the investigators performed an abdominal MRI without gadolinium.

- The volunteers classified as healthy based on the research conducted by clinicians of primary medical care (control group)

Exclusion Criteria:

- other accompanied diseases than acute pancreatitis (the patients groups)

- Individuals of the control group with diagnosed disease as well as alcohol and drugs abusers

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Wroclaw Medical University

Outcome

Type Measure Description Time frame Safety issue
Other The estimation of the concentration of vascular endothelium damage marker (endothelin) in the blood 3 months
Other The estimation of the concentration of total cholesterol in the blood 3 weeks
Other The estimation of the concentration of triglycerides in the blood 3 weeks
Other The estimation of the concentration of low-density lipoprotein (LDL) in the blood 3 months
Other The estimation of the concentration of high-density lipoprotein (HDL) in the blood 3 weeks
Other The estimation of endocrine functions of pancreas measured by the concentration of insulin in the blood 2 months
Other The estimation of endocrine functions of pancreas measured by the concentration of glucagon in the blood 1 month
Other The estimation of endocrine functions of pancreas measured by the concentration of pancreatic polypeptide in the blood 1 month
Other The estimation of endocrine functions of pancreas measured by the concentration of somatostatin in the blood 1 month
Other The estimation of endocrine functions of pancreas measured by the concentration of ghrelin in the blood 2 weeks
Other The estimation of exocrine functions of pancreas measured by the activity of amylase and lipase in the blood 3 months
Primary Pro-inflammatory effect of tobacco smoke exposure measured by hsCRP concentration in the blood of patients with acute pancreatitis 3 weeks
Primary Pro-inflammatory effect of tobacco smoke exposure measured by Interleukin-6 concentration in the blood of patients with acute pancreatitis 2 weeks
Secondary The estimation of antioxidant status measured by the activities of antioxidant enzymes in the blood 12 months
Secondary The estimation of antioxidant status measured by small molecular antioxidants concentration in the blood 3 months
Secondary The estimation of prooxidant status measured by the concentration of lipids peroxidation products in the blood 2 months
Secondary The estimation of prooxidant status measured by the concentration of advanced oxidation protein products in the blood 1 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting NCT04195347 - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Phase 1/Phase 2
Completed NCT04735055 - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed NCT02928718 - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated NCT02885441 - Treatment of Acute Pancreatitis With Ketorolac Phase 4
Completed NCT02563080 - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Recruiting NCT01626911 - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis N/A
Completed NCT01507766 - The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Phase 4
Completed NCT04901949 - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting NCT04814693 - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis N/A
Completed NCT02743364 - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis Phase 2
Recruiting NCT05281458 - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections N/A
Not yet recruiting NCT04990336 - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis N/A
Not yet recruiting NCT03259880 - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals N/A
Completed NCT02543658 - Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension Phase 2
Recruiting NCT06023771 - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting NCT05501314 - Remote Home Monitoring Acute Pancreatitis N/A
Completed NCT02897206 - Imipenem Prophylaxis in Patients With Acute Pancreatitis Phase 4
Recruiting NCT03634787 - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting NCT04989166 - Effect of Nano-curcumin Supplementation in Acute Pancreatitis N/A